human K562 cells |
Cytotoxic assay |
|
|
|
Cytotoxicity against human K562 cells by MTT assay, IC50=31.83 nM |
18538567 |
human KB cells |
Cytotoxic assay |
|
|
|
Cytotoxicity against human KB cells by microplate method, IC50=0.6 μM |
14640524 |
human MDA-MB-468 cells |
Cytotoxic assay |
|
48 h |
|
Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride, GI50=2.81 μM |
19945197 |
human MCF7 cells |
Cytotoxic assay |
|
48 h |
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay in presence of 0.4 uM 1-(1-(4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one, GI50=5.51 μM |
19945197 |
human MDA-MB-231 cells |
Cytotoxic assay |
|
48 h |
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride, GI50=6.08 μM |
19945197 |
human HeLa cells |
Cytotoxic assay |
|
|
|
Cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay, IC50=30 μM |
24354322 |
human HepG2 cells |
Cytotoxic assay |
|
48 h |
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay, IC50=37.68 μM |
23815186 |
mammary tumor FM3A |
Cytotoxicity assay |
|
|
|
Cytotoxicity of compound was tested against mouse mammary tumor FM3A cells, EC50 = 0.0000003 μM. |
12570385 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against Plasmodium falciparum FcB1/Columbia infected in human red blood cells assessed as parasite growth inhibition after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.00011 μM. |
25659770 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine and pyrimethamine-resistant ring stage Plasmodium falciparum V1/S infected in human red blood cells after 48 hrs, IC50 = 0.0055 μM. |
21207937 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against Plasmodium ovale ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay, IC50 = 0.0078 μM. |
20937779 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine-sensitive erythrocytic stage of Plasmodium falciparum NF54 infected in human red blood cells assessed as growth inhibition after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.0094 μM. |
23685569 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.01 μM. |
21155593 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay, IC50 = 0.011 μM. |
28222317 |
red blood cells |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically, IC50 = 0.012 μM. |
25311562 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against Plasmodium malariae ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay, IC50 = 0.014 μM. |
20937779 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine-sensitive, mefloquine-resistant ring stage Plasmodium falciparum D6 infected in human red blood cells after 48 hrs, IC50 = 0.0142 μM. |
21207937 |
red blood cells |
Antiplasmodial assay |
|
72 hrs |
|
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human red blood cells after 72 hrs by parasite lactate dehydrogenase assay, IC50 = 0.0143 μM. |
22917857 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against asexual erythrocyte stage of chloroquine-sensitive Plasmodium falciparum NF54 infected in human red blood cells after 48 hrs by lactate dehydrogenase assay, IC50 = 0.016 μM. |
30296683 |
red blood cells |
Antimalarial assay |
|
96 hrs |
|
Antimalarial activity against wild type early trophozoite stage of Plasmodium falciparum D6 in human red blood cells assessed as [3H]hypoxanthine uptake after 96 hrs, IC50 = 0.017 μM. |
23448281 |
FM3A |
Function assay |
|
|
|
Selectivity for FM3A cells over Plasmodium falciparum as mean EC50 ratio, IC50 = 0.019 μM. |
12408708 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.02 μM. |
21155593 |
red blood cells |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically, IC50 = 0.02 μM. |
25311562 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against ring stage Plasmodium falciparum 3D7 infected with human red blood cells incubated for 48 hrs by SYBR Green method, IC50 = 0.023 μM. |
25725608 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against Plasmodium ovale trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay, IC50 = 0.0232 μM. |
20937779 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against Plasmodium falciparum 3D7 A infected in red blood cells assessed as inhibition of [3H]hypoxanthine incorporation after 24 hrs by scintillation counting, IC50 = 0.024 μM. |
24900261 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum Nigerian infected in human red blood cells after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.025 μM. |
28800458 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human red blood cells assessed as reduction in parasite growth after 48 hrs by Hoechst 33342 staining based flow cytometric analysis, IC50 = 0.026 μM. |
30199706 |
HCT-8 |
Antimicrobial assay |
|
48 hrs |
|
Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA, IC50 = 0.027 μM. |
18591280 |
red blood cells |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human type A-positive red blood cells assessed as parasite lactate dehydrogenase activity after 72 hrs by spectrophotometric analysis, IC50 = 0.029 μM. |
22054038 |
red blood cells |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human A-positive red blood cells after 72 hrs by lactate dehydrogenase assay, IC50 = 0.03 μM. |
21123074 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in red blood cells after 72 hrs by SYBR green 1 staining based fluorometric assay, IC50 = 0.03 μM. |
27692831 |
3D7 |
Antiplasmodial assay |
|
|
|
Antiplasmodial activity against Plasmodium falciparum 3D7 ring stage cells assessed as reduction parasitemia by Malstat assay, IC50 = 0.03 μM. |
22858300 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against Plasmodium falciparum 3D7A infected in red blood cells assessed as inhibition of parasite growth after 24 hrs by [3H]hypoxanthine incorporation assay, IC50 = 0.036 μM. |
25906200 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in human red blood cells assessed as reduction in parasitic LDH activity by Malstat reagent based spectrophotometric method, IC50 = 0.04 μM. |
28800458 |
red blood cells |
Antiplasmodial assay |
|
|
|
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay, IC50 = 0.04 μM. |
28315598 |
red blood cells |
Antiplasmodial assay |
|
|
|
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by parasitic LDH assay, IC50 = 0.04 μM. |
24900509 |
Vero |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs, IC50 = 0.05 μM. |
19833520 |
red blood cells |
Antiplasmodial assay |
|
4 hrs |
|
Antiplasmodial activity against Plasmodium falciparum in human red blood cells after 4 hrs, IC50 = 0.055 μM. |
17990865 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine-sensitive ring stage Plasmodium falciparum 3D7 infected in human red blood cells after 48 hrs, IC50 = 0.089 μM. |
21207937 |
B-cells |
Function assay |
|
|
|
Concentration required for half-maximal inhibition of CpG-ODN effect on thymidine uptake by WEHI 231 murine B-cells in the presence of alpha-sIgM., EC50 = 0.11 μM. |
10406648 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine and pyrimethamine resistant Plasmodium falciparum K1 infected in human red blood cells assessed as reduction in parasite viability after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.12 μM. |
25746816 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine/pyrimethamine-resistant Plasmodium falciparum K1 infected in human red blood cells assessed as [3H]-hypoxanthine incorporation incubated for 48 hrs prior to [3H]-hypoxanthine addition measured after 24 hrs by li, IC50 = 0.125 μM. |
24268543 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against Plasmodium malariae trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay, IC50 = 0.1279 μM. |
20937779 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcB1 infected in human red blood cells after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.132 μM. |
28800458 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine-resistant ring stage Plasmodium falciparum W2 infected in human red blood cells after 48 hrs, IC50 = 0.138 μM. |
21207937 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells assessed as inhibition of ring-stage parasite growth after 48 hrs by flow cytometry, IC50 = 0.14 μM. |
21295887 |
RPMI1640 |
Antiparasitic assay |
|
72 hrs |
|
Antiparasitic activity against chloroquine-resistant erythrocytic stage of Plasmodium falciparum K1 infected in human RPMI1640 cells after 72 hrs by NBT staining based spectroscopic analysis, IC50 = 0.14 μM. |
26922226 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine/pyrimethamine resistant Plasmodium falciparum K1 infected in human red blood cells after 48 hrs by [3H]hypoxanthine incorporation assay, IC50 = 0.15 μM. |
27344215 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against asexual erythrocyte stage of chloroquine-resistant Plasmodium falciparum Dd2 infected in human red blood cells after 48 hrs by lactate dehydrogenase assay, IC50 = 0.15 μM. |
30296683 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected in human red blood cells assessed as 3H-hypoxanthine incorporation after 48 hrs by liquid scintillation counting, IC50 = 0.17 μM. |
21644541 |
L6 |
Antiparasitic assay |
|
48 hrs |
|
Antiparasitic activity against Plasmodium falciparum K1 infected in rat L6 cells assessed as inhibition of parasite growth preincubated for 48 hrs before [3H]hypoxanthine addition measured after 24 hrs by [3H]hypoxanthine incorporation assay, IC50 = 0.178 μM. |
21937228 |
L6 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against rat L6 cells by alamar blue assay, IC50 = 0.1885 μM. |
17178177 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against the multidrug-resistant Plasmodium falciparum FRC-3 infected in human red blood cells assessed as reduction in parasite growth after 48 hrs by Hoechst 33342 staining based flow cytometric analysis, IC50 = 0.207 μM. |
30199706 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine-resistant erythrocytic stage of Plasmodium falciparum K1 infected in human red blood cells assessed as growth inhibition after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.21 μM. |
23685569 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine- and pyrimethamine-resistant Plasmodium falciparum K1 infected in human red blood cells assessed as [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting, IC50 = 0.22 μM. |
21438586 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against ring stage Plasmodium falciparum W2 infected with human red blood cells incubated for 48 hrs by flow cytometry, IC50 = 0.229 μM. |
25725608 |
L6 |
Antiparasitic assay |
|
|
|
Antiparasitic activity against chloroquine, pyrimethamine-resistant Plasmodium falciparum K1 erythrocyte stage infected rat L6 cells, IC50 = 0.23 μM. |
17949068 |
L6 |
Antiplasmodial assay |
|
|
|
Antiplasmodial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 infected in rat L6 cells, IC50 = 0.25 μM. |
19942439 |
red blood cells |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human A-positive red blood cells after 72 hrs by lactate dehydrogenase assay, IC50 = 0.25 μM. |
21123074 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcM29 infected in human red blood cells after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.26 μM. |
28800458 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against multidrug-resistant Plasmodium falciparum TM90-C2B infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.28 μM. |
21155593 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against ring stage Plasmodium falciparum Dd2 infected with human red blood cells incubated for 48 hrs by SYBR Green method, IC50 = 0.285 μM. |
25725608 |
red blood cells |
Antimalarial assay |
|
96 hrs |
|
Antimalarial activity against chloroquine and pyrimethamine-resistant early trophozoite stage of Plasmodium falciparum W2 in human red blood cells assessed as [3H]hypoxanthine uptake after 96 hrs, IC50 = 0.29 μM. |
23448281 |
red blood cells |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically, IC50 = 0.316 μM. |
25311562 |
red blood cells |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay, IC50 = 0.317 μM. |
28222317 |
red blood cells |
Antiplasmodial assay |
|
72 hrs |
|
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells after 72 hrs by parasite lactate dehydrogenase assay, IC50 = 0.3171 μM. |
22917857 |
red blood cells |
Antiplasmodial assay |
|
72 hrs |
|
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells after 72 hrs by parasitic LDH assay, IC50 = 0.39 μM. |
24900509 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.4 μM. |
21155593 |
red blood cells |
Antimalarial assay |
|
|
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells assessed as reduction in parasitic LDH activity by Malstat reagent based spectrophotometric method, IC50 = 0.42 μM. |
28800458 |
red blood cells |
Antiplasmodial assay |
|
72 hrs |
|
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay, IC50 = 0.43 μM. |
28315598 |
Vero |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs, IC50 = 0.484 μM. |
19833520 |
HEK293 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay, IC50 = 0.49 μM. |
29236492 |
red blood cells |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human type A-positive red blood cells assessed as parasite lactate dehydrogenase activity after 72 hrs by spectrophotometric analysis, IC50 = 0.52 μM. |
22054038 |
red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells after 48 hrs by SYBR test, IC50 = 0.59 μM. |
26988303 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against multidrug-resistant Plasmodium falciparum TM93-C1088 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.62 μM. |
21155593 |
Dd2 |
Antiplasmodial assay |
|
|
|
Antiplasmodial activity against drug resistant Plasmodium falciparum Dd2 ring stage cells assessed as reduction parasitemia by Malstat assay, IC50 = 0.71 μM. |
22858300 |
red blood cells |
Antimalarial assay |
|
72 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells after 72 hrs by SYBR green 1 staining based fluorometric assay, IC50 = 0.75 μM. |
27692831 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine, pyrimethamine, and mefloquine-resistant Plasmodium falciparum Dd2 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.98 μM. |
21155593 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay, CC50 = 1.6 μM. |
25791675 |
HepG2 |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis, IC50 = 1.65 μM. |
25791675 |
WI38 |
Antiviral assay |
|
2 hrs |
|
Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay, EC50 = 1.7 μM. |
17893158 |
HeLa |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 100 uM ZnCl2, GI50 = 2.1 μM. |
19748786 |
SMB |
Antiprion assay |
|
|
|
Antiprion activity against Chandler strain of sheep scrapie prion protein infected in mouse SMB cells assessed as clearance of disease-associated scrapie prion protein, EC50 = 2.3 μM. |
21570837 |
HEK293 |
Function assay |
|
|
|
Inhibition of human ERG expressed in HEK293 cells assessed as reduction in tail current at membrane potential of +20 mV, IC50 = 2.5 μM. |
25746816 |
red blood cells |
Antimalarial assay |
|
24 hrs |
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in red blood cells assessed as reduction in mature schizonts formation after 24 hrs by Giemsa-staining based assay, EC50 = 2.97 μM. |
29499486 |
HEK293 |
Function assay |
|
|
|
hERG binding assays: Displacement of [3H]-Dofetilide (5 nM final) from hERG membranes obtained from HEK293 cells, Ki = 3.16228 μM. |
32353859 |
1205 Lu |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human 1205 Lu cells after 72 hrs by MTT assay, IC50 = 3.6 μM. |
25699157 |
LN229 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human LN229 cells after 72 hrs by MTT assay, IC50 = 3.6 μM. |
25699157 |
C8161 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human C8161 cells after 72 hrs by MTT assay, IC50 = 3.6 μM. |
25699157 |
HT-29 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 3.6 μM. |
25699157 |
WI38 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human WI38 cells assessed as inhibition of proliferation after 24 hrs by SRB assay, IC50 = 3.63 μM. |
25461309 |
ScN2a |
Function assay |
|
|
|
Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells, EC50 = 4 μM. |
12904059 |
HepG2 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human HepG2 cells after 24 hrs by neutral red dye uptake assay, TC50 = 4.3 μM. |
22783984 |
HeLa |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 50 uM CuCl2, GI50 = 4.4 μM. |
19748786 |
HeLa |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 10 uM CuCl2, GI50 = 5.3 μM. |
19748786 |
HeLa |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 50 uM ZnCl2, GI50 = 5.6 μM. |
19748786 |
HeLa |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 1 uM CuCl2, GI50 = 6.1 μM. |
19748786 |
SH-SY5Y |
Function assay |
|
24 hrs |
|
Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 40 residues) production measured after 24 hrs, IC50 = 7 μM. |
29559198 |
SH-SY5Y |
Function assay |
|
24 hrs |
|
Inhibition of BACE1 in human SH-SY5Y cells harboring wild type APP695 assessed as reduction in amyloid beta (1 to 40) level after 24 hrs by ELISA method, IC50 = 7 μM. |
30268822 |
CHO |
Function assay |
|
|
|
Inhibition of human ERG expressed in CHO cells, Ki = 7.5 μM. |
24900603 |
L6 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against L6 cells, IC50 = 7.7 μM. |
17280835 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay, IC50 = 8.3 μM. |
21155593 |
WI38 |
Cytotoxicity assay |
|
2 hrs |
|
Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay, CC50 = 8.5 μM. |
17893158 |
HepG2 |
Antimalarial assay |
|
|
|
Antimalarial activity against sporozoite stage of Plasmodium berghei yoelii infected in human HepG2 cells, IC50 = 9 μM. |
26640981 |
SKHep |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human SKHep cells after 48 hrs by MTT assay in presence of 10% FBS supplemented DMEM medium, GI50 = 9.5 μM. |
19748786 |
HeLa |
Cytotoxicity assay |
|
7 hrs |
|
Cytotoxicity against human HeLa cells assessed as cell survival after 7 hrs by MTT assay, IC50 = 9.665 μM. |
17768052 |
HeLa |
Cytotoxicity assay |
|
7 days |
|
Cytotoxicity against human HeLa cells after 7 days by MTT assay, IC50 = 9.67 μM. |
21489789 |
K562 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human K562 cells assessed as radioactive thymidine incorporation after 24 hrs, CC50 = 9.7 μM. |
18680278 |
Vero |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against chikungunya virus Indian ocean strain 899 infected in Vero cells assessed as virus-induced cytopathic effect after 6 to 7 days, EC50 = 10 μM. |
25970561 |
PDAC |
Function assay |
|
|
|
Inhibition of cell proliferation of PDAC cells (unknown origin), IC50 = 10 μM. |
26135471 |
Vero |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cell death after 6 to 7 days by MTS assay, EC50 = 10 μM. |
24926807 |
HepG2 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay, EC50 = 10.1 μM. |
29800827 |
BT-483 |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human BT-483 cells after 48 hrs by MTT assay in presence of 10% FBS supplemented DMEM medium, GI50 = 10.2 μM. |
19748786 |
Vero |
Antiviral assay |
|
5 days |
|
Antiviral activity against Chikungunya virus Indian Ocean 889 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTS/PMS method, EC50 = 11 μM. |
29336951 |
Vero A |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Chikungunya virus Indian ocean strain 899 infected in African green monkey Vero A cells assessed as reduction in viral-induced cytopathic effect after 6 to 7 days by MTS/PMS assay, EC50 = 11 μM. |
28671832 |
Vero |
Antiviral assay |
|
5 days |
|
Antiviral activity against Chikungunya virus Indian Ocean strain 899 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured on day 5 post infection by MTS/PMS assay, EC50 = 11 μM. |
29499487 |
Vero |
Antiviral assay |
|
7 days |
|
Antiviral activity against Chikungunya virus Indian Ocean strain 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 7 days by MTS/PMS method, EC50 = 11 μM. |
24800626 |
Vero |
Antiviral assay |
|
7 days |
|
Antiviral activity against Sindbis virus strain HRsp infected in african green monkey Vero cells assessed as inhibition of virus induced cell death measured after 7 days, EC50 = 11 μM. |
25946116 |
Vero |
Antiviral assay |
|
7 days |
|
Antiviral activity against Chikungunya virus strain 899 infected in african green monkey Vero cells assessed as inhibition of virus induced cell death measured after 7 days, EC50 = 11 μM. |
25946116 |
Vero |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Sindbis virus HRsp infected in African green monkey Vero cells assessed as inhibition of virus-induced cell death after 6 to 7 days by MTS assay, EC50 = 11 μM. |
24926807 |
Vero |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Sindbis virus HRsp infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay, EC50 = 11 μM. |
23215460 |
Vero |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Chikungunya virus 899 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay, EC50 = 11 μM. |
23215460 |
red blood cells |
Antimalarial assay |
|
48 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum K14 infected in human red blood cells after 48 hrs by [3H]hypoxanthine incorporation assay, IC50 = 11 μM. |
25282260 |
red blood cells |
Antimalarial assay |
|
24 hrs |
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum RKL9 infected in red blood cells assessed as reduction in mature schizonts formation after 24 hrs by Giemsa-staining based assay, EC50 = 11.25 μM. |
29499486 |
MCF7 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human MCF7 cells assessed as [3H]hypoxanthine incorporation, IC50 = 12 μM. |
18512987 |
HEK293 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HEK293 cells after 72 hrs by alamar blue assay, IC50 = 12 μM. |
21155593 |
Vero |
Antiviral assay |
|
24 hrs |
|
Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as inhibition of viral RNA replication after 24 hrs by RT-PCR method, EC50 = 12 μM. |
28068604 |
Vero |
Antiviral assay |
|
24 hrs |
|
Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as inhibition of viral RNA replication after 24 hrs by RT-PCR method, EC50 = 12 μM. |
28092859 |
HeLa |
Antiviral assay |
|
48 hrs |
|
Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry, IC50 = 12.48 μM. |
22858300 |
SH-SY5Y |
Function assay |
|
24 hrs |
|
Inhibition of BACE1 in human SH-SY5Y cells harboring wild type APP695 assessed as reduction in amyloid beta (1 to 42) level after 24 hrs by ELISA method, IC50 = 12.7 μM. |
30268822 |
SH-SY5Y |
Function assay |
|
24 hrs |
|
Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 42 residues) production measured after 24 hrs by ELISA, IC50 = 12.8 μM. |
29559198 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by Alamar Blue assay, IC50 = 12.9 μM. |
21190857 |
Vero |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Semliki forest virus Vietnam infected in African green monkey Vero cells assessed as inhibition of virus-induced cell death after 6 to 7 days by MTS assay, EC50 = 13.8 μM. |
24926807 |
Vero |
Antiviral assay |
|
7 days |
|
Antiviral activity against Semliki forest virus strain Vietnam infected in african green monkey Vero cells assessed as inhibition of virus induced cell death measured after 7 days, EC50 = 14 μM. |
25946116 |
Vero |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Semliki forest virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay, EC50 = 14 μM. |
23215460 |
NSO |
Cytotoxicity assay |
|
|
|
Cytotoxicity against mouse NSO cells by MTT assay, TC50 = 14.9 μM. |
19113955 |
L1210 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation by Coulter counter analysis, IC50 = 15 μM. |
26114811 |
Huh-7 |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against Plasmodium berghei liver stage form transfected in human Huh-7 cells assessed as cell viability after 48 hrs by luciferase reporter gene assay, IC50 = 15.9 μM. |
23273038 |
Daudi |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human Daudi cells by MTT assay, TC50 = 16.7 μM. |
19113955 |
HeLa |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation by Coulter counter analysis, IC50 = 18 μM. |
26114811 |
J774.1 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against mouse J774.1 cells after 24 hrs by AlamarBlue based cytotoxicity assay, IC50 = 18.4 μM. |
27316542 |
HeLa |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS supplemented DMEM medium, GI50 = 18.6 μM. |
19748786 |
MCF7 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, CC50 = 19.4 μM. |
20014857 |
MCF7 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MCF7 cells after 48 hrs by XTT reduction assay, CC50 = 19.4 μM. |
24686013 |
MCF7 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by XTT assay, CC50 = 19.4 μM. |
24594524 |
MDA-MB-468 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay, IC50 = 19.86 μM. |
26602827 |
KB |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human KB cells after 48 hrs by MTT assay, IC50 = 20.4 μM. |
11809075 |
Vero |
Antiviral assay |
|
5 days |
|
Antiviral activity against Chikungunya virus Indian Ocean 889 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTS/PMS method, EC90 = 21 μM. |
29336951 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Chikungunya virus Indian Ocean strain 899 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured on day 5 post infection by MTS/PMS assay, EC90 = 21 μM. |
29499487 |
Vero |
Antiviral assay |
|
7 days |
|
Antiviral activity against Chikungunya virus Indian Ocean strain 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 7 days by MTS/PMS method, EC90 = 21 μM. |
24800626 |
Vero |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay, IC50 = 21 μM. |
23727538 |
HepG2 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human HepG2 cells after 48 hrs by lactate dehydrogenase assay, GI50 = 22.16 μM. |
21882831 |
KB |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human KB cells after 72 hrs by MTS assay, IC50 = 22.5 μM. |
19879150 |
MDA-MB-231 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay, GI50 = 22.52 μM. |
19804979 |
MDA-MB-231 |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human p53, pRB mutant and estrogen receptor deficient MDA-MB-231 cells after 48 hrs by SRB assay, GI50 = 22.52 μM. |
20561720 |
MDA-MB-231 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay, IC50 = 22.52 μM. |
28586716 |
CEM |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation by Coulter counter analysis, IC50 = 23 μM. |
26114811 |
CE81T |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human CE81T cells after 48 hrs by MTT assay in presence of 10% FBS supplemented DMEM medium, GI50 = 23.4 μM. |
19748786 |
MCF7 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell number incubated for 72 hrs, IC50 = 23.43 μM. |
26135471 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells assessed as intracellular ATP level after 72 hrs by Celltiter-Glo luminescent assay, EC50 = 25 μM. |
21910466 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell number incubated for 72 hrs, IC50 = 25 μM. |
26135471 |
BxPC3 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human BxPC3 cells after 72 hrs by SRB method, IC50 = 25 μM. |
25699157 |
MDA-MB-468 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay, GI50 = 28.58 μM. |
19804979 |
MDA-MB-468 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay, GI50 = 28.58 μM. |
20106668 |
MDA-MB-468 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay, IC50 = 28.58 μM. |
28586716 |
K562 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human K562 cells by MTT assay, IC50 = 29.03 μM. |
18562202 |
HeLa |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay, IC50 = 29.96 μM. |
26602827 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, IC50 = 30 μM. |
19482476 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, IC50 = 30 μM. |
19926173 |
HepG2 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human HepG2 cells by MTT assay, IC50 = 30 μM. |
17981462 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. |
21741131 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. |
22889559 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. |
24946216 |
SH-SY5Y |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay, CC50 = 30 μM. |
29559198 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. |
24858543 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay, CC50 = 30 μM. |
27155463 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay, CC50 = 30 μM. |
25791675 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay, CC50 = 30 μM. |
25282267 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. |
21852132 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. |
22608675 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay, CC50 = 30 μM. |
27654395 |
KB |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human KB cells by SRB assay, ED50 = 30.8 μM. |
16562832 |
HepG2 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by neutral red uptake assay, TC50 = 31 μM. |
23145816 |
K562 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human K562 cells after 72 hrs by flow cytometry, IC50 = 32 μM. |
19482476 |
K562 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human K562 cells after 72 hrs by flow cytometry, IC50 = 32 μM. |
19926173 |
FM3A |
Antiproliferative assay |
|
|
|
Antiproliferative activity against Mouse mammary tumor FM3A cells, EC50 = 32 μM. |
10966746 |
FM3A |
Cytotoxicity assay |
|
|
|
In vitro cytotoxicity against mouse mammary FM3A cells, EC50 = 32 μM. |
12036365 |
FM3A |
Cytotoxicity assay |
|
|
|
Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host, EC50 = 32 μM. |
11855978 |
FM3A |
Cytotoxicity assay |
|
|
|
Cytotoxicity against FM3A mouse mammary cells, EC50 = 32 μM. |
13678413 |
FM3A |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against mouse FM3A cells assessed as inhibition of increase in cell density after 48 hrs, EC50 = 32 μM. |
18479926 |
FM3A |
Cytotoxicity assay |
|
|
|
Compound was tested for cytotoxicity against FM3A mouse mammary cells. , EC50 = 32 μM. |
10447961 |
LNCAP |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human LNCAP cells assessed as reduction in cell number incubated for 72 hrs, IC50 = 32.87 μM. |
26135471 |
HCT116 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HCT116 cells after 72 hrs by WST1 assay, IC50 = 33.7 μM. |
12398531 |
KB |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human KB cells after 72 hrs by SRB assay, ED50 = 33.7 μM. |
9917283 |
KB |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human KB cells after 72 hrs by Alamar blue assay, IC50 = 34 μM. |
24900724 |
CHO |
Cytotoxicity assay |
|
|
|
Cytotoxicity against CHO cells by MTT assay, IC50 = 35.8 μM. |
26832222 |
KB |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human KB cells assessed as growth inhibition, IC50 = 35.95 μM. |
21705220 |
MCF7 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 36.1 μM. |
19892554 |
MDA-MB-231 |
Antiproliferative assay |
|
72 hrs |
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay, IC50 = 36.53 μM. |
26602827 |
NFF |
Cytotoxicity assay |
|
3 days |
|
Cytotoxicity against human NFF cells after 3 days by sulforhodamine B assay, IC50 = 37.3 μM. |
23117170 |
MCF7 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay, GI50 = 38.44 μM. |
19804979 |
MCF7 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay, GI50 = 38.44 μM. |
20106668 |
p53+/- MCF7 |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human p53+/- MCF7 cells after 48 hrs by SRB assay, GI50 = 38.44 μM. |
20561720 |
MCF7 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay, IC50 = 38.44 μM. |
28586716 |
Caco2 |
Antiproliferative assay |
|
2 days |
|
Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay, GI50 = 38.67 μM. |
24184076 |
THP1 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human THP1 cells by MTT assay, IC50 = 40 μM. |
17981462 |
THP1 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry, IC50 = 40 μM. |
19748781 |
THP1 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay, IC50 = 40 μM. |
19914747 |
THP1 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human THP1 cells using propidium iodide staining after 72 hrs by flow cytometry, IC50 = 40 μM. |
20638854 |
HEK293 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay, IC50 = 40 μM. |
28774427 |
NCH-89 |
Antiproliferative assay |
|
48 hrs |
|
Antiproliferative activity against human carmustine-resistant NCH-89 cells assessed as BrdU incorporation after 48 hrs, IC50 = 41.2 μM. |
20329733 |
HepG2 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 48 hrs by LDH assay, GI50 = 43.09 μM. |
25684422 |
L6 |
Toxicity assay |
|
|
|
Toxicity against rat L6 cells, IC50 = 43.1 μM. |
19781948 |
KB |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human KB cells after 72 hrs by alamar blue assay, CC50 = 44 μM. |
20014857 |
MKN28 |
Antiproliferative assay |
|
2 days |
|
Antiproliferative activity against human MKN28 cells after 2 days by sulforhodamine B assay, GI50 = 44.44 μM. |
24184076 |
NFF |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human NFF cells, IC50 = 46.608 μM. |
30245402 |
J774 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay, EC50 = 47.2 μM. |
29215279 |
HEK293 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against HEK293 cells after 72 hrs by Alamar Blue assay, IC50 = 48 μM. |
21190857 |
MRC5 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against MRC5 cells |
17166718 |
HeLa |
Function assay |
10 uM |
1 hr |
|
Stimulation of reactive oxygen species in human HeLa cells at 10 uM in presence of 10 uM CuCl2 after 1 hr by dihydroethidium dye based fluorescence assay |
19748786 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
DAOY |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells |
29435139 |
Saos-2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells |
29435139 |
RD |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells |
29435139 |
BT-37 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells |
29435139 |
BT-12 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells |
29435139 |
NB1643 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |
HEK293 |
Autophagy assay |
10 uM |
8 hrs |
|
Induction of autophagy in HEK293 cells assessed as increase in p62 level at 10 uM after 8 hrs by immunoblot analysis |
28481536 |
HEK293 |
Autophagy assay |
10 uM |
8 hrs |
|
Induction of autophagy in HEK293 cells assessed as increase in LC3-2 level at 10 uM after 8 hrs by immunoblot analysis |
28481536 |
LNCAP |
Function assay |
|
|
|
Reduction in GFP expression in human LNCAP cells transfected with plasmids co-expressing GFP and shRNAs against REV-ERBbeta followed by compound treatment 24 hrs post-transfection and measured 48 hrs post dose |
26135471 |
SKBR3 |
Function assay |
|
|
|
Reduction in GFP expression in human SKBR3 cells transfected with plasmids co-expressing GFP and shRNAs against REV-ERBbeta followed by compound treatment 24 hrs post-transfection and measured 48 hrs post dose |
26135471 |
HepG2 |
Function assay |
|
|
|
Reduction in GFP expression in human HepG2 cells transfected with plasmids co-expressing GFP and shRNAs against REV-ERBbeta followed by compound treatment 24 hrs post-transfection and measured 48 hrs post dose |
26135471 |
H460 |
Apoptosis assay |
25 to 75 uM |
24 hrs |
|
Induction of apoptosis in human H460 cells at 25 to 75 uM after 24 hrs by annexin-V staining-based flow cytometry |
25699157 |
HepG2 |
Function assay |
50 uM |
6 hrs |
|
Reduction in lysosomal acidification in human HepG2 cells at 50 uM after 6 hrs by DAPI/lyso tracker red-double staining based confocal microscopic analysis relative to control |
28197320 |